Join our innovative clinical trial evaluating an investigational medication that is being researched to potentially treat fatty liver disease in adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Those who qualify and choose to participate may be compensated up to $3,925 for 19 in-clinic visits and 4 remote visits over approximately 5 years and 4 months. .
This study is designed to evaluate the safety and effectiveness of pegozafermin, an investigational injection, for liver fibrosis stage F2 or F3 in adult participants with MASH. Pegozafermin is thought to boost and enhance the action of a natural hormone that helps correct problems with how the body handles fats and sugars, with the goal of reducing liver fat, calming liver inflammation, and slowing or reversing liver scarring in people with MASH.
The study is randomized, double-blind, and placebo-controlled to ensure high-quality, unbiased results. If you qualify and choose to participate, there is a 67% chance you will receive the study treatment and a 33% chance you will receive a placebo. A placebo is an inactive material that looks like the study drug but does not contain any active ingredient.
You will be in this study for approximately 5 years and 4 months which will include a screening period, a treatment period, and a follow up period. The study will require up to 19 in-clinic visits and 4 remote visits. If you qualify and choose to participate, you may be compensated up to $3,925 for your study-related time and travel. There may also be a possibility to join an open label extension following participation where the active drug will be received. Your participation is entirely voluntary, and you can leave the study at any time.
Those who qualify and choose to participate could receive:
Access to the investigational fatty liver disease treatment at no cost
Access to our top-tier team of board-certified physicians at no cost
Compensation up to $3,925 for 19 in-clinic visits and 4 telephone visits over about 5 years and 4 months
A research study or clinical trial is the process a potential new drug, device, procedure, or process goes through to prove that it is safe, tolerable and effective for the condition it is being studied for. Research studies are the only way to advance medicine for future generations.
Each study has its own set of inclusion and exclusion criteria that a participant must meet before they are allowed to participate in a study. Patients from all backgrounds and walks of life are encouraged to participate.
Every participant in every research study must go through the informed consent process. During this, the trial doctor and research team go over what will happen in the study, what treatments you might get, how long the trial is expected to last, what happens during visits, the potential risks and benefits, and many other important facts about the study. Participants may withdraw their consent and discontinue the study at any time for any reason.
A placebo looks like a treatment but does not have any active medicine in it. Researchers use placebos to help make sure any changes in the participants’ health are actually caused by the study treatment. You do not get to choose if you get the study treatment or the placebo, and you may not know if you get the placebo until after the study. Not all research studies use a placebo.
If studies do not include diverse participants, we cannot know if treatments work for everyone who needs them. Studies only tell researchers how something works for the participants of that study, and they may not work the same in people of different races, ethnicities, ages, or sexes.
All research studies must follow federal laws and ethical guidelines, including HIPAA. Studies must also be reviewed by an expert group called an institutional review board (IRB) that helps make sure the trial is fair and as safe as possible, and that any risks to the participants are worth the potential benefits.